Premium
A proposed staging system for chronic myeloid leukemia
Author(s) -
Ross Dennis W.,
Brunning Richard D.,
Kantarjian Hagop M.,
Phillip Koeffler H.,
Ozer Howard
Publication year - 1993
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19930601)71:11<3788::aid-cncr2820711150>3.0.co;2-7
Subject(s) - medicine , myeloid leukemia , chromosomal translocation , breakpoint cluster region , bone marrow , philadelphia chromosome , abl , chromosome , myeloid , cancer research , staging system , myeloproliferative disorders , leukemia , oncogene , pathology , cancer , gene , genetics , biology , tyrosine kinase , receptor , cell cycle
A staging system was proposed for chronic myeloid leukemia (CML) that groups patients into three stages (I, II, and III), each with two subclasses (A and B). The system uses pathologic parameters, of which the percentage of blasts in the blood and bone marrow is the most important. CML is defined as a myeloproliferative disorder with molecular or cytogenetic evidence of the translocation of the abl oncogene on chromosome 9 to the breakpoint cluster region gene on chromosome 22. The proposed staging system is similar in format to the standard TNM system used for many solid tumors.